Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02_V) in healthy adults

References

• Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: A historical overview. Vaccine 2008; 26:6266 - 6273
   PubMed Web of Science ®Google Scholar
• Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11:97 - 107
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Hepatitis B. Fact sheet N°204 2010 Revised August 2008. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/
   Google Scholar
• Wong PN, Fung TT, Mak SK, Lo KY, Tong GM, Wong Y, et al. Hepatitis B virus infection in dialysis patients. J Gastroenterol Hepatol 2005; 20:1641 - 1651
   PubMed Web of Science ®Google Scholar
• Peces R, Laurés AS. Persistence of immunologic memory in long-term hemodialysis patients and healthcare workers given hepatitis B vaccine: role of a booster dose on antibody response. Nephron 2001; 89:172 - 176
   PubMed Web of Science ®Google Scholar
• Bel'eed K, Wright M, Eadington D, Farr M, Sellars L. Vaccination against hepatitis B infection in patients with end stage renal disease. Postgrad Med J 2002; 78:538 - 540
   PubMed Web of Science ®Google Scholar
• DaRoza G, Loewen A, Djurdjev O, Love J, Kempston C, Burnett S, et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kid Dis 2003; 42:1184 - 1192
   PubMed Web of Science ®Google Scholar
• Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007; 6:723 - 739
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMEA). European Public Assessment Reports (EPARs) for authorized medicinal products for human use. Fendrix. EPAR H-C-50 2010 Available at: http://www.emea.europa.eu/humandocs/Humans/EPAR/fendrix/fendrix.htm
   Google Scholar
• Surquin M, Tielemans C, Kulcsár I, Ryba M, Vörös P, Mat O, et al. Rapid, enhanced and persistent protection of patients with renal insufficiency by AS02V-adjuvanted hepatitis B vaccine. Kidney Int 2010; 77:247 - 255
   PubMed Web of Science ®Google Scholar
• Vandepapelière P, Horsmans Y, Moris P, Van Mechelen M, Janssens M, Koutsoukos M, et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 2008; 26:1375 - 1386
   PubMed Web of Science ®Google Scholar
• Sezer S, Ozdemir FN, Güz G, Arat Z, Colak T, Sengul S, et al. Factors influencing response to hepatitis B virus vaccination in hemodialysis patients. Transplant Proc 2000; 32:607 - 608
   PubMed Web of Science ®Google Scholar
• Ramezani A, Velayati AA, Eslamifar A, Banifazl M, Ahmadi F, Maziar S, et al. Persistence of hepatitis B vaccine immunity in hemodialysis patients. Ther Apher Dial 2008; 12:143 - 146
   PubMed Web of Science ®Google Scholar
• Ramezani A, Eslamifar A, Banifazl M, Ahmadi F, Maziar S, Razeghi E, et al. Efficacy and long-term immunogencitiy of hepatitis B vaccine in haemodialysis patients. Int J Clin Pract 2009; 63:394 - 397
   PubMed Web of Science ®Google Scholar
• Salisbury DM, Begg NT. Immunisation against Infectious Diseases 1996; London HM Stationary Office 95 - 108
   Google Scholar
• Impfempfehlungen der ständigen impfkommission (STIKO) an RKI. Epidemiogisches Bulletin No. 2 2000; Berlin Robert Koch Institut
   Google Scholar
• Keating GM, Noble S. Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. Drugs 2003; 63:1021 - 1051
   PubMed Web of Science ®Google Scholar
• Barry M, Cooper C. Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy. Expert Opin Biol Ther 2007; 7:1731 - 1737
   PubMed Web of Science ®Google Scholar
• Halperin SA, Dobson S, McNeil S, Langley JM, Smith B, McCall-Sani R, et al. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine 2006; 24:20 - 26
   PubMed Web of Science ®Google Scholar
• Jilg W, Schmidt M, Deinhardt F, Zachoval R. Hepatitis B vaccination: how long does protection last?. Lancet 1984; 458
   PubMed Web of Science ®Google Scholar
• Jilg W, Schmidt M, Deinhardt F. Persistence of specific antibodies after hepatitis B vaccination. J Hepatol 1988; 6:201 - 207
   PubMed Web of Science ®Google Scholar
• European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity?. Lancet 2000; 355:561 - 565
   PubMed Web of Science ®Google Scholar
• Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 2005; 11:63 - 68
   PubMed Web of Science ®Google Scholar
• Kong NCT, Beran J, Kee SA, Miguel JL, Sánchez C, Bayas JM, et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int 2005; 68:2298 - 2303
   PubMed Web of Science ®Google Scholar
• Kong NCT, Beran J, Kee SA, Miguel JL, Sánchez C, Bayas JM, et al. A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kidney Int 2008; 73:856 - 862
   PubMed Web of Science ®Google Scholar
• Kundi M. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines 2007; 6:133 - 140
   PubMed Web of Science ®Google Scholar
• Beran J. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-hemodialysis and hemodialysis patients. Expert Opin Biol Ther 2008; 8:235 - 247
   PubMed Web of Science ®Google Scholar
• Bojang KA. RTS,S/AS02A for malaria. Expert Rev Vaccines 2006; 5:611 - 615
   PubMed Web of Science ®Google Scholar
• Progress in the control of viral hepatitis: memorandum from a WHO meeting. Bull World Health Organ 1988; 66:443 - 455
   PubMed Web of Science ®Google Scholar
• Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee. MMWR 1991; 40:1 - 25
   PubMedGoogle Scholar